Arteriosclerosis (e.g., Atherosclerosis, Etc.) Affecting Patents (Class 514/1.9)
  • Patent number: 12002199
    Abstract: The present disclosure includes methods, apparatuses, and systems for three-dimensional phenotyping and physiologic characterization of brain lesions and tissue encompassing one or more enlarged boundaries surrounding the brain lesion to study the metabolic and physiologic profiles from tissue within and around lesions and their impacts on lesion shape and surface texture. The non-invasive biomarker blood-oxygen their impacts on lesion shape and surface texture. The non-invasive biomarker blood-oxygen-level-dependent (BOLD) slope was used to metabolically characterize lesions. Metabolically active lesions with more intact tissue and myelin architecture have more symmetrical shapes and more complex surface textures compared to metabolically inactive lesions with less intact tissue and myelin architecture.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: June 4, 2024
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Darin T. Okuda, Dinesh K. Sivakolundu
  • Patent number: 11752197
    Abstract: Methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC) are provided herein.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: September 12, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Julie Horowitz, Aris Baras, Manuel Allen Revez Ferreira
  • Patent number: 11747082
    Abstract: Provided is a multi-part lyophilization container for lyophilizing a fluid, storing the lyophilizate, reconstituting the lyophilizate, and infusing the reconstituted lyophilizate into a patient, including a method of using same. The container includes a front surface, a back surface, a non-breathable section including a port region, a breathable section including a breathable membrane, and a peelable region including a peelable seal encompassing a boundary between the non-breathable section and the breathable section. The method includes inputting a fluid into a non-breathable section of the container, freezing the fluid, applying, in a lyophilization chamber, vacuum pressure, opening the peelable seal using a pressure differential, applying heat energy, sublimating the fluid and creating a temporary occlusion in a peelable region of the container.
    Type: Grant
    Filed: November 28, 2022
    Date of Patent: September 5, 2023
    Assignee: Terumo BCT Biotechnologies, LLC
    Inventors: Kestas P. Parakininkas, Eric T. Hansen, Kirk L. Weimer, Nathaniel T. Johnson, Dennis J. Hlavinka
  • Patent number: 11738096
    Abstract: The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: August 29, 2023
    Assignees: Yale University, University of Rhode Island Board of Trustees
    Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
  • Patent number: 11740231
    Abstract: Provided are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a marker by assaying a biological sample from a subject that is a candidate for treatment, optionally with a cell therapy, to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS. In some embodiments, the methods and articles of manufacture further includes a regent for assaying the biological sample and instructions for determining the percentage or number of cells positive for the marker in the biological sample.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: August 29, 2023
    Assignee: Juno Therapeutics, Inc.
    Inventors: Nathan Yee, Christopher Glen Ramsborg, Tina Albertson, Ryan Larson, He Li
  • Patent number: 11510874
    Abstract: A method for making reduction sensitive nano micelles comprising: 1) dissolving taurine in distilled water, and adding sodium hydroxide solution; 2) dissolving acryloyl chloride in dichloromethane, reacting at 25° C.; dissolving lipoic acid in toluene and adding hydroxyethyl methacrylate, reacting at 85° C.; 3) dissolving N-acryloyltaurine and lipoic acid methacryloyloxyethyl ester and reacting at 60˜65° C., dropping the polymer solution into deionized water, adding dithiothreitol and reacting at 25˜30° C. to obtain reduction sensitive nano micelles after freeze-drying. The nano micelles have regular morphology and uniform distribution, and can be used as drug carriers for controlled release.
    Type: Grant
    Filed: December 31, 2020
    Date of Patent: November 29, 2022
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Liping Zhang, Caihua Ni, Xinxin Sang, Gang Shi
  • Patent number: 11358932
    Abstract: Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: June 14, 2022
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventor: Bing Wang
  • Patent number: 11352405
    Abstract: The present invention relates to the medical use of specific GLP-1/glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: June 7, 2022
    Assignee: SANOFI
    Inventors: Aimo Kannt, Maximilian Bielohuby, Ralf Elvert, Michael Wagner, Martin Bossart, Torsten Haack, Stephanie Keil, Werner Seiz
  • Patent number: 11268964
    Abstract: The present invention provides biomarkers of oxidative stress in subjects with retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, Fuchs' dystrophy, diabetic macular edema (DME), geographic atrophy, Stargardt's disease, or retinal vein occlusion (RVO), and their use in identifying subjects in need of treatment and methods for staging the severity of the disease.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: March 8, 2022
    Assignee: The Johns Hopkins University
    Inventors: Peter A. Campochiaro, Lili Lu
  • Patent number: 11207369
    Abstract: Disclosed herein are methods for modifying ciliogenesis in one or more cells of a subject, the method comprising administering to the subject an effective amount of a composition comprising a Notch signaling inhibitor, wherein the modification results in an increase in a number of cilia, an increase in a length of cilia, and/or an increase in a beat frequency of cilia as compared to a control. Also disclosed herein are methods for modifying ciliogenesis in one or more cells of a subject, the method comprising administering to the subject from 0.1 ?g/kg to 100 g/kg of a Notch signaling inhibitor. In some embodiments, the methods can be used to treat Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Asthma, Primary Ciliary Dyskinesia (PCD), Cystic Fibrosis (CF), or hydrocephalus.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: December 28, 2021
    Assignee: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Maliha Zahid, Cecilia Wen Ya Lo
  • Patent number: 11167014
    Abstract: The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: November 9, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Andreas Vegge, Susanne Scheele, Simon Bjerregaard
  • Patent number: 11154595
    Abstract: The present invention relates to a method for preventing and treating pulmonary fibrosis, comprising administering an effective amount of plasminogen to a subject.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: October 26, 2021
    Assignee: Talengen International Limited
    Inventor: Jinan Li
  • Patent number: 11136372
    Abstract: The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: October 5, 2021
    Assignees: The United States of America, as represented by the Secretary, Dept. of Health & Human Services, Novo Nordisk A/S
    Inventors: Alan Thomas Remaley, Soumitra Shanker Ghosh, Madhav N. Devalaraja, Chih-Hung Lo, Denis O. Sviridov, Anna Wolska
  • Patent number: 11129900
    Abstract: The purpose of the present invention is to provide a novel system for the delivery of a drug to a posterior segment of the eye. The present invention relates to: a cytophilic peptide-fused high-density lipoprotein (cHDL) which can be used as a carrier for the delivery of a drug to a posterior segment of the eye; a method for producing the cytophilic peptide-fused high-density lipoprotein; a system of the delivery of a drug to a posterior segment of the eye, a pharmaceutical composition, and a system of the delivery of a drug to a posterior segment of the eye, each of which utilizes the cytophilic peptide-fused high-density lipoprotein; and a method for diagnosing, preventing or treating posterior ocular disease.
    Type: Grant
    Filed: December 25, 2015
    Date of Patent: September 28, 2021
    Assignees: KYOTO UNIVERSITY, NOSTA AG
    Inventors: Kenji Suda, Tatsuya Murakami, Nagahisa Yoshimura, Norimoto Gotoh
  • Patent number: 11090372
    Abstract: The present invention relates to the effect of plasminogen in the prevention and/or treatment of diabetic nephropathy. Compared with other existing drugs for treating diabetic nephropathy, the plasminogen of the present invention has significant effects of improving renal microvascular injury, reducing glomerular basement membrane and glomerular mesangial thickening, and the like.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: August 17, 2021
    Assignee: TALENGEN INTERNATIONAL LIMITED
    Inventor: Jinan Li
  • Patent number: 11091529
    Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimers Disease or frontotemporal dementia.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: August 17, 2021
    Assignee: The Regents of the University of California
    Inventors: John K. Bielicki, Jan Johansson
  • Patent number: 11015179
    Abstract: The present specification relates to an anti-viral composition and, more particularly, to a composition that both is anti-viral and prevents and treats diseases associated with viruses, containing a peptide derived from a telomerase, thereby being effective in treating and preventing diseases associated with viruses and pathological symptoms caused by viruses. The peptide exhibits an effect of treating diseases associated with viruses by inhibiting the RNA replication of viruses, thereby being capable of providing a method that both is antiviral and prevents and treats diseases associated with viruses.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: May 25, 2021
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 10913780
    Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) including but not limited to conjugates comprising FK-506 and ascomycin. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating. Further embodiments include methods for making the inventive compound. Additional embodiments of the invention are also discussed herein.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: February 9, 2021
    Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Joseph A. Fuselier, David H. Coy
  • Patent number: 10766939
    Abstract: The present invention relates to amylin analogs and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogs have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 8, 2020
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Oliver Demmer, Lise Giehm, Jesper Sloth Villadsen, Henrik Munch, Jesper Mosolff Mathiesen, Jolanta Skarbaliene, Maria Deryabina, Dieter Wolfgang Hamprecht
  • Patent number: 10752664
    Abstract: Methods of treating metabolic diseases and disorders using a GDF15 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: August 25, 2020
    Assignee: AMGEN INC.
    Inventors: YuMei Xiong, Yang Li, Wen-Chen Yeh, Bei Shan, Jackie Zeqi Sheng
  • Patent number: 10583174
    Abstract: The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 10, 2020
    Assignee: SANOFI
    Inventors: Britta Göbel, Mark Sommerfeld, Oliver Boscheinen, Thomas Langer, Christine Rudolph, Andreas Evers
  • Patent number: 10519211
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: December 31, 2019
    Assignee: SANOFI
    Inventors: Martin Bossart, Andreas Evers, Torsten Haack, Katrin Lorenz, Dieter Kadereit, Michael Wagner, Stefania Pfeiffer-Marek, Martin Lorenz
  • Patent number: 10071140
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: September 11, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Jesper Mosolff Mathiesen, Jesper Skodborg Villadsen, Lise Giehm, Henrik Kofoed Munch, Dieter Wolfgang Hamprecht, Alexander Heim-Riether, Giacomo Fossati
  • Patent number: 10046025
    Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a cyclic polypeptide.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: August 14, 2018
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Patent number: 10035778
    Abstract: The present disclosure provides pharmaceutical agents of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: July 31, 2018
    Assignee: Saint Louis University
    Inventors: Peter G. Ruminski, David W. Griggs
  • Patent number: 10016480
    Abstract: Methods for treating a subject for pancreatic cancer via administration of small anti-inflammatory peptides are disclosed. The peptides may be administered in conjunction with another therapeutic agent, such as a chemotherapeutic agent, or therapeutic regimen. In some cases, the anti-inflammatory peptide that finds use in the subject methods has the amino acid sequence Lys-Phe-Arg-Lys-Ala-Phe-Lys-Arg-Phe-Phe (SEQ ID NO:1) or a multimer, derivative, or variant thereof.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: July 10, 2018
    Assignees: The United States of America, as Represented by the Secretary, Dept. of Health and Human Services, Riptide Bioscience, Inc.
    Inventors: Udo Rudloff, Jesse M. Jaynes, Henry W. Lopez, George R. Martin, Clayton Yates
  • Patent number: 10005829
    Abstract: The invention relates to novel compositions comprising modified apelin-13 peptide sequences designed to treat cardiovascular disease in subjects to whom they are administered, and which exhibit greater resistance to degradation, and equivalent or greater bioactivity than their wild type counterparts. The invention also relates to methods of making said compositions and using said compositions as pharmaceutically active agents to treat cardiovascular disease.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: June 26, 2018
    Assignee: NOVARTIS AG
    Inventors: Frederic Zecri, Kayo Yasoshima, Philipp Grosche, Jun Yuan, Hongjuan Zhao
  • Patent number: 9988421
    Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R1-R10, X, Y, k, m, n, q, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: June 5, 2018
    Assignee: Cornell University
    Inventors: Gang Lin, Carl Nathan, Aihao Ding, Xiaojing Ma
  • Patent number: 9968654
    Abstract: The problem to be solved by the present invention is to provide a safe and efficacious therapeutic agent for dermatitis which is not only safe and efficacious for patients with dermatitis, in particular atopic dermatitis, but also significantly effective for severe cases that are judged to be intractable by conventional external preparations, and which is also safely applicable to affected areas such as the face and neck, as well as to subjects with sensitive skin, such as infants and females. Furthermore, the invention aims to provide an external preparation that is efficacious as skin care cosmetics having effects to improve elasticity and wrinkles of the skin, moisturizing effects, and hair-growth effects. The means for solving the problem is a skin external-preparation composition, in particular, a therapeutic agent for dermatitis or a skin texture-improving agent, having C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: May 15, 2018
    Assignee: IGISU CO., LTD.
    Inventor: Kyoko Endo
  • Patent number: 9963498
    Abstract: A fusion peptides with sequences derived from the extracellular domain of syndecan-1 that inhibits VLA-4 and IGF-1R signaling are disclosed. The fusion peptides include an IGF-1R-binding segment having the amino acid sequence LPAGEGPKEGEAVVLPEVEPGLTAREQ (SEQ ID NO:1) and a VLA-4-binding segment having the amino acid sequence sequence DFTFETSGENTA (SEQ ID NO:2).
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: May 8, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Alan C. Rapraeger, DeannaLee M. Beauvais, Oisun Jung
  • Patent number: 9908919
    Abstract: The invention provides a synthetic polypeptide of Formula I (SEQ ID NO: 1): X1-R-X3-R-L-X6-X7-K-X9-P-X11-X12-X13??I or an amide, an ester, a salt thereof, or a bioconjugate thereof, wherein X1, X3, X6, X7, X9, X11, X12 and X13 are defined herein. The polypeptides and bioconjugates are agonist of the APJ receptor.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: March 6, 2018
    Assignee: NOVARTIS AG
    Inventors: Frederic Zecri, Philipp Grosche, Kayo Yasoshima, Hongjuan Zhao, Jun Yuan
  • Patent number: 9867829
    Abstract: The present invention relates to a stable pharmaceutical composition comprising amorphous or crystalline linagliptin or a pharmaceutically acceptable salt of linagliptin, mannitol, copovidone, and magnesium stearate, processes for preparing the stable pharmaceutical composition, and a container comprising the stable pharmaceutical composition.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: January 16, 2018
    Assignee: SANDOZ AG
    Inventors: Franz X. Schwarz, Georg Anker, Johann Bacher, Andreas Hotter
  • Patent number: 9827219
    Abstract: The present disclosure provides methods for treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. In some embodiments, the method comprises lowering high sensitivity CRP (hs-CRP) levels in a subject including, for example, a subject with a HbA1c value of about 5.00 %-8.50 % or at least about 6.8 %.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: November 28, 2017
    Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
  • Patent number: 9783616
    Abstract: The invention provides methods and cells for improved transplantation of donor transplants to subjects in need thereof.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: October 10, 2017
    Assignee: University of Connecticut
    Inventors: Linda H. Shapiro, Jiyeon K. Denninger
  • Patent number: 9683018
    Abstract: The invention provides a synthetic polypeptide of Formula I?: X1-R-P-R-X5-X6-X7-K-X9-P-X11-X12-X13 or an amide, an ester, a salt or a bioconjugate thereof, wherein X1, X5, X6, X7, X9 and X11 to X13 are defined herein. The polypeptides and bioconjugates are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides or bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: June 20, 2017
    Assignee: NOVARTIS AG
    Inventors: Frederic Zecri, Philipp Grosche, Kayo Yasoshima, Hongjuan Zhao, Jun Yuan
  • Patent number: 9616100
    Abstract: The present invention relates to novel therapies that utilize exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of exogenous HSP70.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: April 11, 2017
    Assignee: ALTERNATIVE INNOVATIVE TECHNOLOGIES LLC
    Inventors: Sergei B Onikienko, Alex Nivorozhkin, Alexander V Zemlyanoi
  • Patent number: 9518088
    Abstract: The present invention provides a peptide-phospholipid conjugate of Formula 1: wherein: X is selected from the group consisting of —CR1R2—, —R3—, —O—, —S—, and S+(R3)—; Y is selected from the group consisting of a bond, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; Z is a peptide comprising 1 to 50 amino acids; R1 and R2 each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; and R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, amino, ether, cycloamino, cycloether, ary
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: December 13, 2016
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Michael S. Van Nieuwenhze, William W. Turner, Joseph L. Witztum, Karsten Hartvigsen
  • Patent number: 9434951
    Abstract: Provided herein are methods of decreasing leukocyte extravasation from a lymph or blood vessel into a tissue in a mammal, methods of decreasing fluid leakage from a lymph or blood vessel in a mammal in need thereof, methods of decreasing formation of atherosclerotic plaques in a mammal in need thereof, and methods of treating atherosclerosis in a mammal that include administering to the mammal an oligonucleotide that decreases Mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) mRNA expression in an endothelial cell. Also provided are methods of identifying a candidate agent useful for decreasing leukocyte extravasation or decreasing fluid leakage from a lymph or blood vessel in a mammal, and compositions containing an oligonucleotide that decreases Map4k4 mRNA expression in an endothelial cell and additional therapeutic agents.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: September 6, 2016
    Assignee: University of Massachusetts
    Inventors: Michael P. Czech, Rachel Roth Flach
  • Patent number: 9340582
    Abstract: The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I? (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: May 17, 2016
    Assignee: NOVARTIS AG
    Inventors: Jun Yuan, Frederic Zecri, Philipp Grosche, Hongjuan Zhao, Eric Peters, Shari Lynn Caplan, Changgang Lou
  • Patent number: 9315546
    Abstract: The present invention provides novel peptides that can modulate the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and sub-types, isoforms and variants thereof). These peptides are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperpro-liferative disorders.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: April 19, 2016
    Assignees: The Administrators of the Tulane Educational Fund, McGill University
    Inventors: Cyril Y. Bowers, David H. Coy, Simon J. Hocart, Gloria S. Tannenbaum
  • Patent number: 9125850
    Abstract: Immunostimulatory methods and systems for treating or preventing atherosclerosis and/or a condition associated thereto in an individual.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: September 8, 2015
    Assignee: Cardio Vax, LLC
    Inventors: Kuang-Yuh Chyu, Prediman K. Shah
  • Patent number: 9067971
    Abstract: The invention provides a synthetic polypeptide of Formula I?: or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: June 30, 2015
    Assignee: NOVARTIS AG
    Inventors: Frederic Zecri, Andrei Golosov, Philippr Grosche, Hongjuan Zhao, Qi-Ying Hu, Hidetomo Imase
  • Patent number: 9051393
    Abstract: A method of ameliorating one or more symptoms of an inflammatory condition in a subject comprises the step of administering to the subject a therapeutically effective amount of a polypeptide that is capable promoting cholesterol efflux from lipid loaded cells, the polypeptide consisting of the amino acid sequence of SEQ ID NO:1, in which each X in SEQ ID NO:1 is a phenylalanine amino acid.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: June 9, 2015
    Assignee: The Cleveland Clinic Foundation
    Inventors: Jonathan D. Smith, Stanley L. Hazen
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Publication number: 20150132321
    Abstract: The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis. Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via ?1 integrin activation.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Donald E. Ingber, Charles K. Thodeti
  • Patent number: 9029325
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 12, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
  • Patent number: 9029327
    Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: May 12, 2015
    Assignee: Affiris AG
    Inventors: Günther Staffler, Petra Lührs, Andreas Mairhofer, Frank Mattner, Walter Schmidt, Andrea Dolischka
  • Patent number: 9023789
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analog of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: May 5, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
  • Publication number: 20150104485
    Abstract: Compounds of general formula (I): Ri—Wn—Xm-AAi-AA2-AA3-AA4-AA5-AA6-Yp—Zq—R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, pigmentation disorders and angiogenic skin disorders, and in processes of treatment and/or care of the skin and/or mucous membranes.
    Type: Application
    Filed: April 16, 2013
    Publication date: April 16, 2015
    Applicant: LUBRIZOL ADVANCED MATERIALS, INC.
    Inventors: Jose Maria Garcia Anton, Antonio Vicente Ferrer Montiel, Cristina Carreño Serraïma, Raquel Delgado González, Juan Cebrián Puche
  • Patent number: RE49816
    Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R1-R10, X, Y, k, m, n, q, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: January 30, 2024
    Assignee: CORNELL UNIVERSITY
    Inventors: Gang Lin, Carl Nathan, Aihao Ding, Xiaojing Ma